NYSE - Delayed Quote USD

Ginkgo Bioworks Holdings, Inc. (DNA)

0.8056 -0.0334 (-3.98%)
At close: May 17 at 4:00 PM EDT
0.8149 +0.01 (+1.15%)
After hours: May 17 at 7:59 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
208,697.0000
251,455.0000
477,706.0000
313,837.0000
76,657.0000
Cost of Revenue
40,832.0000
54,005.0000
204,216.0000
129,690.0000
15,611.0000
Gross Profit
167,865.0000
197,450.0000
273,490.0000
184,147.0000
61,046.0000
Operating Expense
898,318.0000
965,646.0000
2,482,442.0000
2,012,614.0000
198,073.0000
Operating Income
-730,453.0000
-768,196.0000
-2,208,952.0000
-1,828,467.0000
-137,027.0000
Net Non Operating Interest Income Expense
54,290.0000
57,124.0000
20,156.0000
-1,536.0000
197.0000
Other Income Expense
-177,770.0000
-181,868.0000
67,397.0000
-8,119.0000
11,996.0000
Pretax Income
-853,933.0000
-892,940.0000
-2,121,399.0000
-1,838,122.0000
-124,834.0000
Tax Provision
-122.0000
-71.0000
-15,027.0000
-1,480.0000
1,889.0000
Net Income Common Stockholders
-853,664.0000
-892,869.0000
-2,108,072.0000
-1,888,662.0000
-126,609.0000
Diluted NI Available to Com Stockholders
-853,664.0000
-892,869.0000
-2,108,072.0000
-1,888,662.0000
-126,609.0000
Basic EPS
-0.43
--
-1.25
-1.35
-0.09
Diluted EPS
-0.43
--
-1.25
-1.39
-0.09
Basic Average Shares
1,966,794.2500
--
1,679,061.0000
1,359,849.0000
1,485,061.2360
Diluted Average Shares
1,966,794.2500
--
1,679,839.0000
1,360,373.0000
1,485,061.2360
Total Operating Income as Reported
-826,663.0000
-864,406.0000
-2,208,952.0000
-1,828,467.0000
-137,027.0000
Total Expenses
939,150.0000
1,019,651.0000
2,686,658.0000
2,142,304.0000
213,684.0000
Net Income from Continuing & Discontinued Operation
-853,811.0000
-892,869.0000
-2,104,929.0000
-1,830,047.0000
-126,609.0000
Normalized Income
-669,028.4034
-704,512.9779
-2,207,728.3320
-1,900,874.1020
-129,932.6900
Interest Income
54,383.0000
57,217.0000
20,262.0000
837.0000
2,582.0000
Interest Expense
--
93.0000
106.0000
2,373.0000
2,385.0000
Net Interest Income
54,290.0000
57,124.0000
20,156.0000
-1,536.0000
197.0000
EBIT
-855,104.0000
-892,847.0000
-2,121,293.0000
-1,835,749.0000
-122,449.0000
EBITDA
-789,639.0000
-821,293.0000
-2,076,870.0000
-1,806,673.0000
-108,585.0000
Reconciled Cost of Revenue
40,832.0000
54,005.0000
204,216.0000
129,690.0000
15,611.0000
Reconciled Depreciation
65,465.0000
71,554.0000
44,423.0000
29,076.0000
13,864.0000
Net Income from Continuing Operation Net Minority Interest
-853,811.0000
-892,869.0000
-2,104,929.0000
-1,830,047.0000
-126,609.0000
Total Unusual Items Excluding Goodwill
-184,809.0000
-188,371.0000
103,524.0000
70,898.0000
4,553.0000
Total Unusual Items
-184,809.0000
-188,371.0000
103,524.0000
70,898.0000
4,553.0000
Normalized EBITDA
-604,830.0000
-632,922.0000
-2,180,394.0000
-1,877,571.0000
-113,138.0000
Tax Rate for Calcs
0.0000
0.0000
0.0000
0.0000
0.0003
Tax Effect of Unusual Items
-26.4034
-14.9779
724.6680
70.8980
1,229.3100
12/31/2020 - 4/19/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

RXRX Recursion Pharmaceuticals, Inc.
9.42
-0.95%
 
CRSP CRISPR Therapeutics AG
56.22
+0.99%
 
NTLA Intellia Therapeutics, Inc.
26.22
+0.19%
 
BEAM Beam Therapeutics Inc.
24.62
+3.49%
 
JAGX Jaguar Health, Inc.
0.2585
-9.84%
 
BLUE bluebird bio, Inc.
1.0300
-1.90%
 
EDIT Editas Medicine, Inc.
5.62
-4.58%
 
IOVA Iovance Biotherapeutics, Inc.
10.24
-1.82%
 
NVAX Novavax, Inc.
13.01
-9.65%
 
IBRX ImmunityBio, Inc.
7.65
-1.29%